NeuroSense Therapeutics Ltd. Finance Income Cost
NeuroSense Therapeutics Ltd. (NRSN) reported Finance Income Cost of $2.02 million for the 12-month period ending 2023-12-31, per its 20-F filed 2024-04-04.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:FinanceIncomeCost · last filed 2024-04-04
| Period end | Finance Income Cost 6 month | Finance Income Cost 12 month |
|---|---|---|
| 2023-12-31 | $2.02M 20-F · filed 2024-04-04 | |
| 2023-06-30 | -$2.00M 6-K · filed 2023-08-16 | |
| 2022-12-31 | $1.21M 20-F · filed 2024-04-04 | |
| 2022-06-30 | $658.00K 6-K · filed 2023-08-16 | |
| 2021-12-31 | $1.55M 20-F · filed 2024-04-04 | |
| 2021-06-30 | $10.00K 6-K/A · filed 2023-01-19 | |
| 2020-12-31 | $60.00K 20-F · filed 2023-03-22 | |
| 2019-12-31 | $13.00K 20-F · filed 2022-04-14 |